Molecular Partners AG(MOLN)Earnings, Financials & Key Ratios
MOLN•NASDAQ
$3.80
Price updated Jun 27, 2026
AboutMolecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Show more
- Revenue$0-100.0%
- EBITDA-$56M+4.9%
- Net Income-$62M-14.1%
- EPS (Diluted)-1.65-3.8%
- ROE-55.55%-63.5%
MOLN Price & Volume
Molecular Partners AG (MOLN) stock price & volume — 10-year historical chart
Loading chart...
Clinical Milestone Dependency Strains Capital Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Milestone Funding Dependency
Key Thesis Takeaways
- Molecular Partners faces a precarious financial outlook characterized by a total reliance on non-recurring milestone payments, as evidenced by revenue growth hitting -100% for multiple consecutive quarters.
- The firm's high-cost Swiss operating model necessitates consistent R&D spending near $10 million per quarter, which continues to erode the asset base from $198.4 million in 2023Q4 to $87.4 million by 2026Q1.
- Investors should monitor the company's ability to secure new partnerships, as the exhaustion of deferred revenue suggests that future liquidity may depend on dilutive financing or further pipeline rights surrender.
Verdict Logic
the company's reliance on sporadic milestone payments and a persistent quarterly cash burn of approximately $13 million creates significant risk of future equity dilution for shareholders.
MOLN Growth Metrics
Molecular Partners AG (MOLN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM2.46%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM9.3%
Return on Capital
10 Years-25.32%
5 Years-20.16%
3 Years-38.03%
Last Year-48.68%
MOLN Recent Earnings
Molecular Partners AG (MOLN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (56%)●Beat Revenue 4/12 qtrs (67%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.45-18.4%
$0.38
Rev
—
—
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.41-2.5%
$0.40
Rev
—
—
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$0.41+10.9%
$0.46
Rev
—
—
Q3 2025
Aug 25, 2025Metric
Actual
Est
EPS
$0.67-26.4%
$0.53
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.45vs $0.38-18.4% | — |
| Q2 2026 | Mar 12, 2026 | $0.41vs $0.40-2.5% | — |
| Q4 2025 | Oct 30, 2025 | $0.41vs $0.46+10.9% | — |
| Q3 2025 | Aug 25, 2025 | $0.67vs $0.53-26.4% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Molecular Partners AG (MOLN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.80 | $142.54M | -1.86 | -100% | — | -55.55% | — | |
| $15.05 | $1.1B | -12.14 | 13.65% | -185.71% | -28.77% | — | |
| $90.00 | $6.83B | -26.87 | -12.38% | -654.43% | -50.62% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $55.08 | $9.18B | 38.52 | -5.25% | 9.78% | 8.82% | — | |
| $31.00 | $3.12B | -9.42 | -4.26% | -156.36% | -68.97% | — |
Compare MOLN vs Peers
Molecular Partners AG (MOLN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when MOLN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MOLN Frequently Asked Questions
Molecular Partners AG (MOLN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is Molecular Partners AG growing?
Molecular Partners AG (MOLN) saw revenue decline by 100.0% over the past year.
Is MOLN profitable?
Molecular Partners AG (MOLN) reported a net loss of $58.0M for fiscal year 2025.
Dividend & Returns
What is MOLN's return on equity?
Molecular Partners AG (MOLN) has a return on equity (ROE) of -55.5%. Negative ROE indicates the company is unprofitable.
What is Molecular Partners AG's free cash flow?
Molecular Partners AG (MOLN) had negative free cash flow of $54.1M in fiscal year 2025, likely due to heavy capital investments.